Recruiting A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors NCT06952010 Conditions Advanced Solid Tumor, Immune Sensitive Tumor, Metastatic Solid Tumor, +6 more Locations Exelixis Clinical Site #5 — San Francisco, California, United States Exelixis Clinical Site #4 — New Haven, Connecticut, United States Exelixis Clinical Site #8 — Tampa, Florida, United States Exelixis Clinical Site #10 — Boston, Massachusetts, United States View more locations Show fewer locations Loading locations... View Trial Details